Cohen I, Shulman A, Altaras M, Tepper R, Cordoba M, Beyth Y
Department of Obstetrics and Gynecology, Sapir Medical Center, Kfar Saba, Israel.
Gynecol Obstet Invest. 1994;38(2):127-9. doi: 10.1159/000292464.
To the best of our knowledge, this is the first report of in vivo endometrial estrogen and progesterone receptor induction as a result of tamoxifen exposure in a postmenopausal breast cancer patient. The following observations, that the postmenopausal endometrium is sensitive to tamoxifen, that this agent can act as an estrogen-like substance, and that it may cause proliferation of the endometrium in the absence of progestin, may explain the endometrial decidual changes described herein as a protective mechanism against possible neoplastic endometrial changes.
据我们所知,这是关于绝经后乳腺癌患者因他莫昔芬暴露导致体内子宫内膜雌激素和孕激素受体诱导的首例报告。以下观察结果,即绝经后子宫内膜对他莫昔芬敏感,该药物可作为一种雌激素样物质,且在无孕激素的情况下可能导致子宫内膜增生,或许可以解释本文所述的子宫内膜蜕膜样改变是一种针对可能的子宫内膜肿瘤性改变的保护机制。